Profile | GDS2987 / GI_31542934-S |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | ||
GSM215244 | HMVEC_vehicle_rep2 | 5.4 | 14 |
GSM215253 | HMVEC_vehicle_rep3 | 30.5 | 63 |
GSM215254 | HMVEC_atorvastatin_rep1 | 13.5 | 34 |
GSM215282 | HMVEC_atorvastatin_rep3 | ||
GSM215344 | HMVEC_atorvastatin_rep2 | 14.2 | 34 |
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | 14.6 | 28 |
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | 1.8 | 4 |
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | 22.8 | 36 |
GSM215294 | HMVEC_SLx2119_rep1 | 1.9 | 7 |
GSM215295 | HMVEC_SLx2119_rep2 | 19.7 | 38 |
GSM215296 | HMVEC_SLx2119_rep3 | 17.3 | 28 |
GSM215297 | PASMC_vehicle_rep1 | 40 | 51 |
GSM215298 | PASMC_vehicle_rep2 | 19.1 | 29 |
GSM215310 | PASMC_vehicle_rep3 | ||
GSM215311 | PASMC_atorvastatin_rep1 | ||
GSM215312 | PASMC_atorvastatin_rep2 | 20.4 | 32 |
GSM215313 | PASMC_atorvastatin_rep3 | 4.6 | 7 |
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | 13.7 | 23 |
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 16.3 | 31 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | ||
GSM215327 | PASMC_SLx2119_rep1 | 18.7 | 32 |
GSM215328 | PASMC_SLx2119_rep2 | 8.8 | 17 |
GSM215329 | PASMC_SLx2119_rep3 | 33.7 | 53 |
GSM215330 | Fibroblasts_vehicle_rep1 | 9.1 | 22 |
GSM215331 | Fibroblasts_vehicle_rep2 | 9.6 | 27 |
GSM215332 | Fibroblasts_vehicle_rep3 | 2.2 | 8 |
GSM215333 | Fibroblasts_atorvastatin_rep1 | 14.5 | 37 |
GSM215334 | Fibroblasts_atorvastatin_rep2 | 9 | 25 |
GSM215335 | Fibroblasts_atorvastatin_rep3 | 4.8 | 13 |
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | 2.5 | 9 |
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | ||
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 10.7 | 29 |
GSM215339 | Fibroblasts_SLx2119_rep1 | 8.1 | 24 |
GSM215340 | Fibroblasts_SLx2119_rep2 | 15 | 39 |
GSM215341 | Fibroblasts_SLx2119_rep3 | 3.1 | 8 |